Journal of Hepatology
Volume 51, Issue 5 , Pages 918-924, November 2009

Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome

  • Ali Abid

      Affiliations

    • Liver Unit, Ziv Medical Center, P.O. Box 1008, 13100 Safed, Israel
    • Department of Internal Medicine, Holy Family Hospital, Nazareth, Israel
  • ,
  • Ola Taha

      Affiliations

    • Department of Internal Medicine, Holy Family Hospital, Nazareth, Israel
  • ,
  • William Nseir

      Affiliations

    • Department of Internal Medicine, Holy Family Hospital, Nazareth, Israel
  • ,
  • Raymond Farah

      Affiliations

    • Department of Internal Medicine, Ziv Medical Center, Safed, Israel
  • ,
  • Maria Grosovski

      Affiliations

    • Department of Biotechnology, Ort-Braude College, Karmiel, Israel
  • ,
  • Nimer Assy

      Affiliations

    • Liver Unit, Ziv Medical Center, P.O. Box 1008, 13100 Safed, Israel
    • Technion Institute, Faculty of Medicine, Haifa, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 46828441; fax: +972 46828442.

Received 1 March 2009; received in revised form 17 May 2009; accepted 30 May 2009. published online 21 August 2009.

Associate Editor: C.P. Day

Background/Aims

The independent role of soft drink consumption in non-alcoholic fatty liver disease (NAFLD) patients remains unclear. We aimed to assess the association between consumption of soft drinks and fatty liver in patients with or without metabolic syndrome.

Methods

We recruited 31 patients (age: 43±12years) with NAFLD and risk factors for metabolic syndrome, 29 patients with NAFLD and without risk factors for metabolic syndrome, and 30 gender- and age-matched individuals without NAFLD. The degree of fatty infiltration was measured by ultrasound. Data on physical activity and intake of food and soft drinks were collected during two 7-day periods over 6months using a food questionnaire. Insulin resistance, inflammation, and oxidant–antioxidant markers were measured.

Results

We found that 80% of patients with NAFLD had excessive intake of soft drink beverages (>500cm3/day) compared to 17% of healthy controls (p<0.001). The NAFLD group consumed five times more carbohydrates from soft drinks compared to healthy controls (40% vs. 8%, p<0.001). Seven percent of patients consumed one soft drink per day, 55% consumed two or three soft drinks per day, and 38% consumed more than four soft drinks per day for most days and for the 6-month period. The most common soft drinks were Coca-Cola (regular: 32%; diet: 21%) followed by fruit juices (47%). Patients with NAFLD with metabolic syndrome had similar malonyldialdehyde, paraoxonase, and C-reactive protein (CRP) levels but higher homeostasis model assessment (HOMA) and higher ferritin than NAFLD patients without metabolic syndrome (HOMA: 8.3±8 vs. 3.7±3.7mg/dL, p<0.001; ferritin: 186±192 vs. 87±84mg/dL, p<0.01). Logistic regression analysis showed that soft drink consumption is a strong predictor of fatty liver (odds ratio: 2.0; p<0.04) independent of metabolic syndrome and CRP level.

Conclusions

NAFLD patients display higher soft drink consumption independent of metabolic syndrome diagnosis. These findings might optimize NAFLD risk stratification.

Abbreviations: NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis

Keywords: Soft drinks, Fatty liver, Risk factors, Fructose, Independent predictor, Metabolic syndrome, Dietary intake

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00532-7

doi:10.1016/j.jhep.2009.05.033

Journal of Hepatology
Volume 51, Issue 5 , Pages 918-924, November 2009